Author(s):
Fahmi Hassan Mohamed, Manikandan K, Lakshmi K S
Email(s):
gurumani12@gmail.com
DOI:
10.5958/0974-360X.2021.00004.4 
Address:
Fahmi Hassan Mohamed, Manikandan K*, Lakshmi K S
Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur–603203, Kanchipuram - District: Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2021
ABSTRACT:
Multivariate calibration technique makes the use for determination of Pioglitazone in bulk drug and pharmaceutical dosage form. This technique is constructed to manipulate statistical calculations, in correlating the relation between concentrations against absorbance at five separate wavelengths. ?max of the Pioglitazone was found to be 218nm. The results were statistically performed and offer ideal outcome by removing variations emerging from the instrumental or experimental conditions. The multivariate technique was approved according to ICH guidelines as well as originated to be sensitive, linear, accurate, precise, and consistent. The graph have been constructed to be straight-line over a concentration ranging from 8–16µg/mL with acceptance value of correlation coefficient (r2) of about 0.9969. Equation of linear regression has shown Y= 0.0486x + 0.1856 and both LOQ as well as LOD was originated to be 1.2765 and 3. 86831µg/mL individually. While %RSD for precision intraday as well as interday have been in range of 0.7343–0.9543 and 0.837–0.901 respectively. The percentage recovery was found within the range of 92.87–99.78% w/w. The results shows that the multivariate technique is simple, linear, precise, accurate, sensitivity and reproducible for the estimation of Pioglitazone in pharmaceutical dosage form.
Cite this article:
Fahmi Hassan Mohamed, Manikandan K, Lakshmi K S. UV Spectrophotometric Estimation of Pioglitazone using Multivariate method in Bulk drug and Pharmaceutical Dosage Form. Research J. Pharm. and Tech. 2021; 14(1):14-20. doi: 10.5958/0974-360X.2021.00004.4
Cite(Electronic):
Fahmi Hassan Mohamed, Manikandan K, Lakshmi K S. UV Spectrophotometric Estimation of Pioglitazone using Multivariate method in Bulk drug and Pharmaceutical Dosage Form. Research J. Pharm. and Tech. 2021; 14(1):14-20. doi: 10.5958/0974-360X.2021.00004.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-4
REFERENCES:
1. http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8228.
2. Lehmann JM, Moore L, Smith-Oliver TA, et al. An antidiabetic, thiazoledinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol. Chem, 1995 June 2; 270(22): 12953–6.
3. G. Belcher, C. Lambert, G. Edwards, et al., Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type2 diabetes, Diabetes Res. Clin.Pract.70(2005)53–62.
4. J.M. Olefsky, Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists, J. Clin. Invest.106 (2000) 467–472.
5. Y. Miyazaki, A. Mahankali, M. Matsuda, et al., Improved glycemic control and enhanced insulin sensitivity in type2 diabetic subjects treated with pioglitazone, Diabetes Care 24 (2001)710–719.
6. Saltiel AR, Olefsky JM. Et al., Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 Dec; 45: 1661–9.
7. Lambe KG, Tugwood JD. Et al., A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biol. chem 1996 Jul 1; 239: 1–7
8. K. Danzer and L. A. Currie, Pure Appl. Chem., 70, 993 (1998).
9. G.R.K. Reddy. V. S. N. Rao, Development and validation of stability indicating assay method for pioglitazone drug substance by reverse phase HPLC J. Global Trends Pharm. Sci. 3(2012)584–596.
10. S. Sharma, M. C. Sharma, S. C. Chaturvedi, Study of stressed degradation behavior of pioglitazone hydrochloride in bulk and pharmaceutical formulation by HPLC assay method, J. O. to electron. Biomed. Mater, 1(2010)17–24.
11. Linda Hammash, Yaser Bitar, Saleh Trefi. Novel Ion Pair HPLC Methods for the Assessment of Sitagliptin and Pioglitazone in Tablets. Research J. Pharm. and Tech 2019; 12(8):3713-3719.
12. Deepa R. Patel, Laxmanbhai J. Patel, Madhabhai M. Patel. Stability Indicating HPLC Method for Simultaneous Determination of Glimepride, Pioglitazone Hydrochloride and Metformin Hydrochloride in Pharmaceutical Dosage Form. Research J. Pharm. and Tech. 2011; 4(4): 606-611
13. A.M.R.L. Saber, Determination of pioglitazone hydrochloride in tablets by high-performance liquid chromatography, Pak .J. Anal. Environ. Chem. 9(2008)118–121.
14. S.C.D. Dhirender Singh, Ashok Kushnoor, Development and validation of HPTLC method for estimation of pioglitazone in bulk and tablet dosage form, J. Pharm. Res. 4(2011)3919–3921.
15. Miral Rank, Pankaj Kapupara, Ketan Shah. Development and Validation of Stability Indicating HPTLC Method for Pioglitazone Hydrochloride and Metformin Hydrochloride. Research J. Pharm. and Tech 2016; 9(10):1555-1561.
16. M. Sharma, S. Sharma, D. Kohli, HPTLC method development and validation for the estimation of atorvastatin calcium and pioglitazone HCl in pharmaceutical combined tablet dosage form, Ann. Biol. Res. 1 (2010)124–129.
17. D.P. Anand, HPTLC method for determination of telmesarton HCl with pioglitazone HCl in pharmaceutical dosage form, Int. J. Pharm. Res. 2(2010)185–190.
18. Asha Byju Thomas, et al. Stability-indicating HPTLC method for simultaneous determination of nateglinide and metformin hydrochloride in pharmaceutical dosage form; Saudi Pharmaceutical Journal. 2011: 221-231.
19. Sethi PD. HPTLC- Qualitative Analysis of Pharmaceutical Formulation. 1st Ed. New Delhi: CBS Publisher and Distributors; 1996: 3-30.
20. K.S. Lakshmi, T. Rajesh, Simultaneous, Determination of Metformin and Pioglitazone by Reversed phase HPLC in Pharmaceutical dosage forms, International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 1, Issue 2, Oct-Dec. 2009
21. Sahoo PK, Sharma R, Chaturvedi SC, Simultaneous Estimation of Metformin hydrochloride and Pioglitazone hydrochloride by RP-HPLC method from combined tablet dosage form, Ind J. Pharm Sci 2008; 70: 383-386.
22. D. Jain, S. Jain, D. Jain, Simultaneous estimation of metformin hydrochloride, pioglitazone HCl, and glimepiride by RP-HPLC in tablet formulation, J. Chromatography. Sci. 46(2008)501–504.
23. M. Sarat, P. M. Krishna, C. Rambabu, RP-HPLC method for estimation of saxagliptin and pioglitazone in tablets, Int. Res. J. Pharm. 3 (2012) 399–402.
24. T.M. Kalyankar, M. R. Badgujar, R. B. Kakde, Simultaneous determination of pioglitazone HCl and glimepiride by RP-HPLC in pharmaceutical dosage form, J. Pharm. Res. 3(2010)3078–3080.
25. D.C. Prem, Anand, K .L. Senthilkumar, B. Senthilkumar, Anew RP-HPLC method development and validation for simultaneous estimation of telmisartan and pioglitazone in pharmaceutical dosage form, Int. J. Chem. Tech Res. 3(2009)448–454.
26. Wanjari DB, Gaikwad NJ. et al., Stability indicating RP-HPLC method for determination of Pioglitazone from Tablets. Ind J pharml sci 2005; 67(2):256-258.
27. Jajow Swapna, et al. Analytical Method Development and Method Validation for the Simultaneous estimation of Metformin hydrochloride and Pioglitazone hydrochloride in Tablet Dosage Form by RP-HPLC; Asian Journal Pharmaceutical Analysis. 2(3); 2012: 85-89.
28. Sachin L. Patil, et al. Development and validation of a stability indicating RP-HPLC method for simultaneous determination of sitagliptin and metformin in tablet dosage form; International Journal of Research in Pharmaceutical and Biomedical Science. 2(5); 2013: 590-596.
29. Chaturvedi PK, Sharma R. Development and Validation of an RP-HPLC method for Simultaneous analysis of a Three-component Tablet Formulation containing Metformin Hydrochloride, Pioglitazone Hydrochloride and glibenclamide. Acta Chromatographica 2008; 20(3):451-461.
30. K.R Sreejith, P.L Rajagopal, K Premaletha. Analytical Method Development and Validation of Anostrozole in Pure and Tablet Dosage Form by UV Spectroscopy. Research J. Pharm. and Tech. 2017; 10(4): 1015-1019.
31. C. Bijithra, G. Ragan, P. Shanmugasundaram. Analytical Method Development and Validation of Modafinil in Pure and Tablet Dosage Form by UV Spectroscopy. Research J. Pharm. and Tech 2016; 9(8):1303-1308.
32. M. Sumithra, P. Yuvanesh, Anamika Mistry. Analytical method development and validation of ambroxol hydrochloride by UV spectroscopy and forced degradation study and detection of stability. Research J. Pharm. and Tech. 2016; 9(7):794-800
33. Rupali Sanjay Joshi, Nilima S. Pawar, Sameer Sarvesh Katiyar, Amol Trimbak Shinde, Devendra Bhaskar Zope. Effective Quantitation of Metronidazole in Injectable Pharmaceutical Dosage Form Using UV Spectroscopy. Research J. Pharm. and Tech. 2012; 5(4): 494-496.
34. S. Kathirvel, V. Sahiti, A. Suneetha. Spectrophotometric Estimation of Risedronate Sodium in Bulk and Pharmaceutical Formulations using Multivariate Technique. Research J. Pharm. and Tech. 2010;3 (4): 1209-1212.
35. Abdul Aziz Ramadan, Hasna Mandil, Mohamad Younes. Development and Validation of Spectrophotometric Determination of Pioglitazone Hydrochloride in Bulk Drug and Pharmaceutical Dosage Form through Ion-Pair Complex Formation using Bromocresol Green. Research J. Pharm. and Tech 2018; 11(8): 3295-3302.
36. Ali m. Y, Swamp P.V, Borgaonkar, Raju S. A, et al UV spectrophotometric determination of pioglitazone in pharmaceutical dosage forms, Int. J. Chem. Sci , 2008;6 ( 4), 2062-2065.
37. Mehta RS, Patel DM, Bhatt KK, Shankar MB, et al., UV and Visible Spectrophotometric analysis of Pioglitazone Hydrochloride in Bulk and Tablets. Ind J Pharm Sci 2005; 67(4):487-489.
38. Chandna Shveta, Kasture AV, Yeole PG. Simultaneous Spectrophotometric determination of Pioglitazone Hydrochloride and Glimepiride in Tablets. Ind J Pharm Sci 2005; 67(5):627-629.
39. Lalhriatpuii TC, Kawathekar N, Derivative Spectrophotometric Estimationof Pioglitazone and Metformin hydrochloride, Ind Drugs 2005; 42: 740-743.
40. Ajithdas A, Nancy K, Simultaneous Estimation of Metformin hydrochloride and Glipizide in Solid Dosage Forms by Ultraviolet Spectrophotometry, Ind Drugs 2000; 37: 533-536.
41. M.D. Game, First order derivative spectrophotometric method for simultaneous estimation of glimepiride and pioglitazone HCl in combined dosage form, J. Pharm. Res. 4(2011)4301–4302.
42. M. Younus Ali, P. V. Swamy, P. Borgaonkar, UV-spectrophotometric determination of pioglitazone in pharmaceutical dosage forms, Int. J. Chem. Sci. 6(2008)2062–2065.
43. S.D. Rathod, P. M. Patil, S. B. Jadhav, UV-spectrophotometric simultaneous determination of metformin HCl and pioglitazone HCl in combined dosage form, Asian J. Pharm. Anal. 2(2012)05–09.
44. P. Shakya, K. Singh, Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by UV-spectrophotometric method, Int. J. Pharm. Sci. Res. 1(2010)153–157.
45. L. Adhikari, S. Jagadev, S. Sahooetal. Development and validation of UV–visible spectrophotometric method for simultaneous determination of pioglitazone HCl, metformin HCl and glipizide in its bulk and pharmaceutical dosage form (tablet), Int. J. Chem. Tech Res. 4 (2012) 625–630.
46. G.A. Mostafa, A. Al-Majed, Characteristics of new composite and classical potentiometric sensors for the determination of pioglitazone in some pharmaceutical formulations, J. Pharm. Biomed. Anal. 48 (2008) 57–61.
47. M. El-Ghobashy, A. Yehia, A. Mostafa, Application of membrane-selective electrodes for the determination of pioglitazone HCl in the presence of its acid degradant or metformin HCl in tablets and plasma, Anal.Lett.42(2009)123–140.
48. F. Faridbod, M.R. Ganjali, E. Nasli-Esfahani, Potentiometric sensor for quantitative analysis of pioglitazone hydrochloride in tablets based on theoretical studies, Int. J. Electrochem.Sci.5 (2010) 880–894.
49. W.A. Badawy, M. A. El-Ries, I. M. Mahdi, Carbonpaste and PVC membrane electrodes as sensitive sensors for the determination of antidiabetic drugs for type2 diabetic patients, Anal. Sci. 25(2009) 1431–1436.
50. Z.J. Lin, W. Ji, D. Desai-Krieger, Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC–MS/MS, J. Pharm. Biomed. Anal. 33(2003)101–108.